Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy

NCT02670603 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02670603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Completed
Start date
August 31, 2015
Completion date
September 30, 2016
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, docetaxel chemotherapy